Literature DB >> 12954480

Diabetes, Alzheimer's disease and apolipoprotein genotype.

Claude Messier1.   

Abstract

Non-insulin dependent diabetes mellitus (NIDDM) has been associated with a number of physiological consequences including neuropathy, retinopathy and incidence of vascular disease. Recently, several authors reviewed studies that suggested that NIDDM is associated with cognitive impairments leading to a higher incidence of dementia and Alzheimer's disease. The current diagnostic practices that typically exclude from an AD diagnostic any patients with suspected vascular dementia, makes it very hard to resolve this issue and likely result in an underestimation of the number of people with Alzheimer's disease and diabetes. When people with cerebrovascular disease are included, diabetes is associated with an increased risk for Alzheimer's disease. Studies that have examined peripheral glucoregulation in Alzheimer's disease are not consistent but some show small to moderate impairments in insulin sensitivity. One recent study suggest that in people that have both diabetes and an ApoE4 allele, the risk of developing Alzheimer's disease is more than double the risk of people with an ApoE4 allele without diabetes. Although diabetes does not produce any of the usual brain pathology associated with Alzheimer's disease, one study has shown that diabetes dramatically increases the amyloid deposition and neurofibrillary tangles in people with the ApoE4 genotype. Taken together, the data available suggest that diabetes is probably a risk factor for Alzheimer's disease mainly through the cerebrovascular disease diabetes causes. In people with other risk factors such as ApoE4 allele, diabetes appears to lead to a more dramatic increase in Alzheimer's disease pathology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954480     DOI: 10.1016/s0531-5565(03)00153-0

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  24 in total

1.  Effect of aldehydes derived from oxidative deamination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer's disease.

Authors:  K Chen; M Kazachkov; P H Yu
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

Review 2.  Non-cognitive symptoms and related conditions in the Alzheimer's disease: a literature review.

Authors:  Francesco Raudino
Journal:  Neurol Sci       Date:  2013-03-31       Impact factor: 3.307

3.  Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status.

Authors:  Michael Malek-Ahmadi; Thomas Beach; Aleksandra Obradov; Lucia Sue; Christine Belden; Kathryn Davis; Douglas G Walker; LihFen Lue; Abdu Adem; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2013-07       Impact factor: 3.498

4.  Apolipoprotein E polymorphisms and spontaneous pregnancy loss in patients with endometriosis.

Authors:  Madeline S Collazo; Tirtsa Porrata-Doria; Idhaliz Flores; Summer F Acevedo
Journal:  Mol Hum Reprod       Date:  2012-01-20       Impact factor: 4.025

Review 5.  Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal.

Authors:  Rajat Sandhir; Smriti Gupta
Journal:  World J Diabetes       Date:  2015-09-25

6.  L-arginine and Alzheimer's disease.

Authors:  Jing Yi; Laura L Horky; Avi L Friedlich; Ying Shi; Jack T Rogers; Xudong Huang
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

7.  Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors.

Authors:  C Messier; M Gagnon
Journal:  Diabetologia       Date:  2009-09-25       Impact factor: 10.122

8.  Presence of the APOE epsilon4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine-Syracuse Study.

Authors:  G A Dore; M F Elias; M A Robbins; P K Elias; Z Nagy
Journal:  Diabetologia       Date:  2009-08-20       Impact factor: 10.122

9.  Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}.

Authors:  Wei-Qin Zhao; Pascale N Lacor; Hui Chen; Mary P Lambert; Michael J Quon; Grant A Krafft; William L Klein
Journal:  J Biol Chem       Date:  2009-04-30       Impact factor: 5.157

10.  APOE genotype modifies the relationship between midlife vascular risk factors and later cognitive decline.

Authors:  Katherine J Bangen; Alexa Beiser; Lisa Delano-Wood; Daniel A Nation; Melissa Lamar; David J Libon; Mark W Bondi; Sudha Seshadri; Philip A Wolf; Rhoda Au
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-04-17       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.